Moderna Sees COVID-19 Vaccine Surplus By 2022 If Constraints Ease
US Asked To Lift DPA Restrictions
Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.
You may also be interested in...
After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.
Some countries want an IP waiver to boost access to vaccines, but industry leaders say this will do nothing to increase output.